The main therapeutic approach designed to target CTGF is the monoclonal antibody pamrevlumab (FG-3019); Pamrevlumab successfully attenuated tumour growth, metastasis and angiogenesis and in a murine PDAC model [107]. Here, CCN2 is linked to neoplasm.